In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Vivo's 2017 Deals Of The Year: The Winners Are…

Executive Summary

We nominated 15 deals in three categories. You picked the winners.

Top Alliance: Regeneron's Novel Deal With Decibel

Regeneron Pharmaceuticals forged a unique agreement with start-up Decibel Therapeutics in which it will make an equity investment and provide financial support for the hearing-focused biotech's R&D, but claim no share of commercial rights to any therapeutics discovered under the collaboration.

Runner-Up: Medtronic & Aetna's outcomes-based insulin pump deal

Top Financing: Pfizer Spins Off SpringWorks

Pfizer's spun out Springworks in September with four clinical-stage assets targeting diseases with no good cures. The big pharma concurrently contributed to SpringWorks $103 million Series A round, as did Bain Capital Life Sciences, Bain Capital Double Impact, Orbimed and LifeArc.

Runner-Up: Silk Road Medical raises $47 million for stroke prevention devices

Top M&A: J&J/Actelion – Win-Win-Win

Johnson & Johnson's months-long pursuit of Actelion Pharmaceuticals culminated in a $30 billion cash acquisition last January. J&J got immediate access to the Swiss biotech's lucrative pulmonary arterial hypertension franchise and late-stage pipeline as well as initial 16% ownership in Idorsia Pharmaceuticals, a new spin-out formed around Actelion's drug discovery operations and early-stage clinical assets.

Runner-Up: CVS/Aetna vertical merger aims to change health care delivery

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts